New Daily Pill to Lower High ("Bad") Cholesterol

Lipfendra (enlicitide; active salt enlicitide decanoate) is a macrocyclic peptide that binds PCSK9 and blocks PCSK9 from tagging LDL receptors for destruction. More receptors stay on the liver cell surface to clear LDL-C from the blood. It is the first FDA-approved oral PCSK9 inhibitor. Injectable monoclonal PCSK9 antibodies (evolocumab, alirocumab) and the siRNA inclisiran already existed; this is a pill, not an injection.

The FDA approved it under NDA 220848 in mid-July 2026 (approval-letter timestamp 15 July 2026; Merck announcement 16 July 2026; FDA press release dated 17 July 2026) as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH. Priority Review and the Commissioner’s National Priority Voucher pilot applied. The holder is Merck Sharp & Dohme LLC.

The US label is explicit about what is and is not proven for this medicine: other LDL-lowering drugs (statins; monoclonal antibody PCSK9 inhibitors added to a statin) have outcomes trials showing fewer major adverse cardiovascular events when LDL-C falls. Lipfendra itself is labelled for LDL-C lowering. Whether Lipfendra reduces heart attacks, strokes, or cardiovascular death is not yet known — that is what CORALreef Outcomes (NCT06008756) is measuring. Do not treat a press release as a MACE claim.

Where this is taking place

Pivotal LDL trials are done. Outcomes follow-up is ongoing and not recruiting.

United States — commercial labelled door. Cardiology, lipidology, or primary care experienced in LDL management writes a 20 mg once-daily prescription under the USPI. Prior authorization and plan coverage still apply. Authorized ≠ funded.

CORALreef Lipids — NCT05952856 — Phase 3, completed. Sponsor: Merck Sharp & Dohme LLC. Adults with hypercholesterolemia (with or without HeFH) and prior major ASCVD or increased risk for a first event, needing more LDL-C lowering on stable moderate- or high-intensity statin (or documented statin intolerance). Actual enrollment 2,912 on CT.gov (2,904 in the USPI analysis set). Randomized 2:1 to enlicitide 20 mg oral once daily or placebo for 52 weeks. Primary efficacy: percent change in LDL-C at Week 24. CT.gov countries included Argentina, China, Colombia, Germany, Israel, Italy, Japan, Mexico, South Africa, South Korea, Spain, Taiwan, Türkiye, United States. No Canadian sites on this record. Completed — not an enrolment path.

CORALreef HeFH — NCT05952869 — Phase 3, completed. Same sponsor. Adults with HeFH needing more LDL-C lowering on stable statin ± other lipid therapy. Actual enrollment 303. Same 20 mg vs placebo design for 52 weeks. CT.gov countries included Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan, United States. Canadian sites ≠ a Canadian licence. Completed — not an enrolment path.

CORALreef Outcomes — NCT06008756 — Phase 3 cardiovascular outcomes, ACTIVE_NOT_RECRUITING. Sponsor: Merck Sharp & Dohme LLC. Estimated enrollment 14,550. Primary: time to first CHD-death–based MACE-plus. Estimated primary completion 29 Nov 2029; estimated study completion 29 Nov 2031. CT.gov countries include Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom, United States. hasExpandedAccess: false. Enrollment is closed. This is not a walk-in clinic to start labelled Lipfendra.

Other CORALreef program studies named in company materials (Extension, Pediatric, Combination, AddOn) are not the US labelled commercial door.

European Union. A paediatric investigation plan (EMEA-003453-PIP01-23) and a CHMP initial-application listing (Enlicitide — EMEA/H/C/006815, adults with primary hypercholesterolaemia or mixed dyslipidaemia, List of questions on the July 2026 CHMP agenda) are not a European Commission marketing authorisation. PIP ≠ MA. CHMP review ≠ licence.

Canada. Trial sites exist on HeFH and Outcomes. No retrieved NOC, DIN, or SUR row for Lipfendra / enlicitide on the Health Canada pages checked for this draft. That is not authorised, not “approved in Canada.”

Approval matrix

Access by country

• United States: Ask the clinician who already manages your lipids (cardiology, lipid clinic, or primary care). FDA-labelled mid-July 2026 for adults needing LDL-C lowering with diet and exercise, including HeFH. Dose: one 20 mg tablet once daily in the morning on an empty stomach with water, black coffee, or plain tea; wait ≥30 minutes before food or other drinks; swallow whole. Can be taken with other medicines. Assess LDL-C when clinically appropriate; effect may be measurable by ~4 weeks. Merck Sharp & Dohme LLC adverse-event / product contact on the USPI: 1-877-888-4231; MedWatch 1-800-FDA-1088. DailyMed / Merck PI host the label. No copay dollars here. Prior authorization still applies. Children not established. Do not treat this as a proven MACE reduction for Lipfendra itself.

• Canada (zoom): Not authorised on sources checked (no NOC/DIN/SUR row retrieved). CORALreef HeFH and Outcomes listed Canadian sites — those trials are completed or closed to enrolment, not a prescription pad. Provincial / territorial / NIHB funding is N/A until there is a NOC. Special Access Programme supply for a non-marketed oral PCSK9: unknown / not confirmed. Do not mail-order a US bottle as a Canadian care plan.

• European Union: CHMP is reviewing EMEA/H/C/006815 (List of questions on the July 2026 agenda). No EC marketing authorisation retrieved. The agreed PIP is paediatric planning only. Wait for an EC decision and a published SmPC before treating an EU pack as real. Do not DIY-import.

• United Kingdom / Australia / Japan / China / Switzerland: Authorisation unknown / not confirmed. Trial sites ≠ licence. Specialist + local named-patient / special-access only if those programs actually apply in writing — not invented here.

If your regulator has not authorised it: do not import on your own.

Who is eligible (from the US label)

United States (USPI / DailyMed):

• Adult (18+).
• Hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
• Use as an adjunct to diet and exercise to reduce LDL-C.
• Recommended dose: one 20 mg tablet orally once daily.
• Pivotal trial populations were on stable moderate- or high-intensity statin (unless statin intolerance was documented), with or without other lipid-modifying therapy; other PCSK9 inhibitors were excluded from Trial 1. The labelled indication wording itself is broader (adjunct to diet/exercise in adults with hypercholesterolemia including HeFH) — your clinician matches the label to your lipid regimen.
• Pediatrics: safety and effectiveness not established.
• Geriatrics: large share of trial patients were ≥65; no overall differences in safety or effectiveness vs younger adults noted on the label.
• Pregnancy: discontinue when pregnancy is recognized unless benefits outweigh potential risks (mechanism may cause fetal harm by lowering cholesterol-derived substances). Human data insufficient.
• Lactation: unknown in human milk; discuss feeding plan with the clinician.
• Renal / hepatic: no clinically meaningful exposure changes described for mild–severe renal impairment or ESRD on dialysis in the PK section; moderate hepatic impairment (Child-Pugh B) OK on PK; severe hepatic impairment (Child-Pugh C) not evaluated.
• Contraindications: none.
• Not a MACE indication for Lipfendra. Outcomes trial ongoing.

Canada / EU / other: no retrieved national label to quote. Eligibility outside the US starts with whether a regulator has authorised the product at all.

What the pivotal studies showed (label vs journal)

Use the USPI for a US prescription conversation. Journals are supportive reading; small number differences are rounding / analysis choices.

Trial 1 — CORALreef Lipids (NCT05952856) — USPI primary numbers

• n=2,904 randomized 2:1 (Lipfendra 1,935 / placebo 969) for 52 weeks; mean baseline LDL-C 96 mg/dL; ~97% on a statin; 58% prior ASCVD event.
• Primary (USPI): mean percent change in LDL-C Week 24 — difference vs placebo −56% (95% CI −61%, −51%; p<0.001). Raw observed means on the label table: Lipfendra −57%, placebo +3%.
• Also at Week 24 vs placebo (USPI table): non-HDL-C difference −53%; ApoB difference −50%.
• LDL-C lowering was sustained through the observed 52-week figure on the label plot.
• Safety (USPI): adverse-reaction frequencies similar to placebo; discontinuation for adverse reactions similar.

Journal (not the label): Navar AM, Mikhailova E, Catapano AL, et al. N Engl J Med. 2026;394:529-539. DOI 10.1056/NEJMoa2511002. Reports adjusted between-group LDL-C difference at Week 24 of −55.8 percentage points (enlicitide mean change −57.1% vs placebo +3.0%), plus significant non-HDL-C, ApoB, and Lp(a) differences. Not a preprint. Prefer USPI −56% language in clinic.

Trial 2 — CORALreef HeFH (NCT05952869) — USPI primary numbers

• n=303 randomized 2:1 (Lipfendra 202 / placebo 101); mean baseline LDL-C 119 mg/dL; all on statin (82% high-intensity); 64% on a cholesterol-absorption inhibitor (e.g. ezetimibe).
• Primary (USPI): mean percent change in LDL-C Week 24 — difference vs placebo −59% (95% CI −66%, −53%; p<0.001). Raw observed means: Lipfendra −58%, placebo +3%.
• Also at Week 24 vs placebo: non-HDL-C difference −53%; ApoB difference −49%.
• Safety (USPI): diarrhea 7% vs 2%; dizziness 9% vs 4%; discontinuations similar to placebo.

Journal (not the label): Ballantyne CM, Gellis L, Tardif JC, et al. JAMA. 2026;335(2):129-139. DOI 10.1001/jama.2025.20620. Reports between-group LDL-C difference −59.4% at Week 24 (−58.2% vs +2.6%). Not a preprint. Prefer USPI −59% language in clinic.

Outcomes — not yet an evidence claim for MACE

CORALreef Outcomes (NCT06008756) is testing whether enlicitide reduces MACE in high-risk people. Status ACTIVE_NOT_RECRUITING; primary completion estimate 2029. Until that reads out and any label is updated, talk about LDL-C lowering, not proven event reduction for Lipfendra.

FDA press (both pivotal LDL trials together): ~3,207 adults; ~56% and ~59% placebo-adjusted LDL-C reductions at Week 24 — consistent with the USPI.

How it is taken (US label — keep this exact)

• One 20 mg tablet orally once daily.
• Take in the morning on an empty stomach with water, black coffee, or plain tea.
• Swallow whole. Do not split, crush, or chew.
• After the dose, wait at least 30 minutes before eating food or drinking anything other than water, black coffee, or plain tea. Food sooner cuts exposure roughly in half.
• Can be taken with other medications.
• Missed dose: take as soon as possible, still ≥30 minutes before the next food/drink (other than water/black coffee/plain tea). Do not take two doses the same day.
• LDL-C effect may be measured as early as ~4 weeks.
• Store 20–25 °C (excursions 15–30 °C) in the original bottle, tightly closed, with desiccant; do not remove the desiccant. Bottle of 30 tablets (NDC 0006-5084-01 on the USPI).

Safety (USPI)

• Contraindications: none.
• Hypercholesterolemia trial (Trial 1): adverse reactions overall similar to placebo; discontinuations similar.
• HeFH trial (Trial 2): most common reactions more frequent than placebo — diarrhea (7% vs 2%) and dizziness (9% vs 4%); otherwise generally consistent with Trial 1; discontinuations similar.
• Pregnancy / lactation: see eligibility; discuss before starting if pregnant, planning pregnancy, or breastfeeding.
• Pediatrics: not established.
• Report suspected adverse reactions to Merck Sharp & Dohme LLC 1-877-888-4231 or FDA MedWatch 1-800-FDA-1088.

No boxed warning on the USPI retrieved for this draft. That is not a claim of “no risk” — it means the label’s main safety story is the trial AE pattern plus pregnancy/mechanism language.

Research team (source-only)

Names and roles as they appear on primary sources — not a clinic directory.

• Merck Sharp & Dohme LLC (Rahway, NJ) — FDA NDA 220848 applicant / DailyMed packager / USPI manufacturer. Adverse reactions contact on label: 1-877-888-4231.
• Merck Sharp & Dohme LLC — lead sponsor, CORALreef Lipids / HeFH / Outcomes (CT.gov). Overall official listed as Medical Director, Merck Sharp & Dohme LLC (title only — no named site PI on these records).
• MSD Europe Belgium S.R.L. — EMA PIP contact organisation (EMEA-003453-PIP01-23); public enquiry email on the PIP page: pip.information@msd.com (PIP administrative contact, not a treating clinic).
• Ann Marie Navar, M.D. — lead author, CORALreef Lipids NEJM paper; quoted in Merck’s approval release as associate professor of medicine, Division of Cardiology, UT Southwestern Medical Center.
• Christie M. Ballantyne, M.D., and coauthors — CORALreef HeFH JAMA paper (Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, et al.).
• Dean Y. Li, M.D., Ph.D. — President, Merck Research Laboratories (company quote on approval).
• Michael Davis, M.D., Ph.D. — Acting Director, FDA CDER (FDA press quote — regulator voice, not a clinic).
• Casey Raudenbush — Senior Director, Regulatory Affairs, addressee on the NDA approval letter (corporate regulatory contact, not a patient hotline beyond the USPI number).

Site-level clinic phone numbers are not listed on these trial records — ask your own lipid clinician, not a directory built from this page.

How to talk to a doctor

Bring the brand, the INN, the NCT numbers, and the regulator that applies:

1. “My LDL-C is still high on diet, exercise, and my current lipid drugs. The FDA labelled Lipfendra (enlicitide) 20 mg once daily in July 2026 as an oral PCSK9 inhibitor. Is that a fit for me — including whether I have HeFH?”
2. “The USPI says take it in the morning on an empty stomach with water, black coffee, or plain tea, wait 30 minutes, swallow whole. Can we walk through how that fits my breakfast and other pills?”
3. “This is labelled to lower LDL-C. The outcomes trial (NCT06008756) is still running — so we should not claim proven heart-attack reduction for Lipfendra itself yet. What is our LDL target and monitoring plan (as early as ~4 weeks)?”
4. “I am / am not on an injectable PCSK9 or inclisiran. The pivotal Lipids trial excluded other PCSK9 inhibitors — how should we sequence or switch?”
5. “Side effects in HeFH looked like more diarrhea and dizziness than placebo; in the broader lipids trial they looked similar to placebo. What should I watch for?”
6. “If I am pregnant, planning pregnancy, or breastfeeding — the label says stop when pregnancy is recognized unless benefits outweigh risks. What is our plan?”
7. If Canada / EU / elsewhere: “Is there a licence in this country yet? I understand US approval is not a Canadian DIN or an EU pack. I will not mail-order. Is Outcomes closed to enrolment here?”
8. “Prior authorization — what does my plan need (LDL labs, HeFH documentation, statin history)?”

Canada zoom: not authorised

There is no retrieved Health Canada Notice of Compliance or DIN for Lipfendra / enlicitide on the sources used for this draft, and no matching row on the new-drug SUR page checked. That is not authorised — not “coming soon,” not a funded provincial drug, and not a reason to order a US bottle online. Canadian sites on CORALreef HeFH (completed) and Outcomes (closed to enrolment) do not create a prescription path. Wait for a real NOC / Product Monograph before treating Canada as labelled.

Bottom line

Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor — 20 mg once daily, morning, empty stomach — labelled mid-July 2026 as an adjunct to diet and exercise to lower LDL-C in adults with hypercholesterolemia, including HeFH. Pivotal CORALreef Lipids and HeFH trials showed roughly 56% and 59% placebo-adjusted LDL-C reductions at Week 24 on the USPI. MACE benefit for this product is not established; CORALreef Outcomes is ongoing and not recruiting. Canada and most other regulators are not confirmed as authorised; the EU has a PIP and a CHMP review, not an EC licence. The practical door in the United States is a lipid-experienced clinician and a labelled prescription. CORALreef Outcomes is closed to enrolment and is not a start path.

---

Primary sources

1. DailyMed LIPFENDRA (enlicitide) tablets, setid 100ec543-fbd0-44fc-b740-db9cdff39145, packager Merck Sharp & Dohme LLC, Revised 7/2026 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=100ec543-fbd0-44fc-b740-db9cdff39145
2. FDA Prescribing Information PDF, NDA 220848, label 220848Orig1s000lbl.pdf — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf
3. Merck USPI host — https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf
4. FDA NDA approval letter, NDA 220848 (letter stamp 07/15/2026) — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf
5. FDA press announcement, 17 July 2026 — https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
6. Merck approval news release, 16 July 2026 — https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/
7. ClinicalTrials.gov CORALreef Lipids NCT05952856 — https://clinicaltrials.gov/study/NCT05952856
8. ClinicalTrials.gov CORALreef HeFH NCT05952869 — https://clinicaltrials.gov/study/NCT05952869
9. ClinicalTrials.gov CORALreef Outcomes NCT06008756 — https://clinicaltrials.gov/study/NCT06008756
10. Navar AM, Mikhailova E, Catapano AL, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394:529-539. DOI 10.1056/NEJMoa2511002 (journal; not the label; not a preprint)
11. Ballantyne CM, Gellis L, Tardif JC, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA. 2026;335(2):129-139. DOI 10.1001/jama.2025.20620 (journal; not the label; not a preprint)
12. EMA PIP EMEA-003453-PIP01-23 (enlicitide decanoate), decision P/0133/2024, 12 Apr 2024 — https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003453-pip01-23
13. CHMP draft agenda 20–23 July 2026, item 3.3.3 Enlicitide — EMEA/H/C/006815 (List of questions) — https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-20-23-july-2026_en.pdf